Cost-effectiveness of daratumumab plus bortezomib and dexamethasone versus bortezomib plus dexamethasone for treatment of patients with multiple myeloma who have received at least one prior therapy

An analysis of the Castor trial

Maiese, E. M., Graham, CN., Hawe, E., Le Moine, J-G., Abraham, I., & Senbetta, M. (2017). Cost-effectiveness of daratumumab plus bortezomib and dexamethasone versus bortezomib plus dexamethasone for treatment of patients with multiple myeloma who have received at least one prior therapy: An analysis of the Castor trial. Blood, 130.

Publications Info

To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.

Recent Publications

Article

The daily association between affect and alcohol use: A meta-analysis of individual participant data
Article

Protection of forest ecosystems in the eastern United States from elevated atmospheric deposition of sulfur and nitrogen
Article

The use of patient experience feedback in rehabilitation quality improvement and codesign activities
Article

SPTSSA variants alter sphingolipid synthesis and cause a complex hereditary spastic paraplegia